RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q1 2019
Top Holdings29 positions
ASCENDIS PHARMA A/S | 4.1M | $486.4M | 21.0% | $59.89 | +96.53% | 2 qtrssince 2018-Q4 | Decreased 0 |
WAVE LIFE SCIENCES LTD | 7.8M | $302.1M | 13.0% | $42.17 | -7.88% | 2 qtrssince 2018-Q4 | Increased 63 |
SYNTHORX INC | 9.7M | $198.1M | 8.5% | — | — | 2 qtrssince 2018-Q4 | Unchanged 0 |
ZOGENIX INC | 2.4M | $131M | 5.7% | — | — | 2 qtrssince 2018-Q4 | Unchanged 0 |
RA PHARMACEUTICALS INC | 4.9M | $108.8M | 4.7% | — | — | 2 qtrssince 2018-Q4 | Unchanged 0 |
INFLARX NV | 2.8M | $106.2M | 4.6% | $36.74 | +2.87% | 2 qtrssince 2018-Q4 | Increased 72 |
ORCHARD THERAPEUTICS PLC | 5.1M | $91.3M | 3.9% | — | — | 2 qtrssince 2018-Q4 | Increased 59 |
EIDOS THERAPEUTICS INC | 2.2M | $91.1M | 3.9% | — | — | 2 qtrssince 2018-Q4 | Unchanged 0 |
MYOVANT SCIENCES LTD | 3.5M | $84.6M | 3.6% | — | — | 2 qtrssince 2018-Q4 | Decreased 0 |
BIOCRYST PHARMACEUTICALS INC | 8.7M | $70.5M | 3.0% | $8.07 | +0.87% | 2 qtrssince 2018-Q4 | Decreased 0 |
TG THERAPEUTICS INC | 8.2M | $65.9M | 2.8% | $3.98 | +102.01% | 2 qtrssince 2018-Q4 | Unchanged 0 |
SAGE THERAPEUTICS INC | 384,001 | $61.1M | 2.6% | — | — | 1 qtr | New 77 |
RHYTHM PHARMACEUTICALS INC | 1.9M | $51.7M | 2.2% | $26.88 | +1.97% | 2 qtrssince 2018-Q4 | Decreased 0 |
AXSOME THERAPEUTICS INC. | 3.3M | $46.9M | 2.0% | $14.23 | 0.00% | 1 qtr | New 77 |
CRINETICS PHARMACEUTICALS IN | 1.9M | $42.7M | 1.8% | $29.99 | -24.11% | 2 qtrssince 2018-Q4 | Unchanged 0 |
KALVISTA PHARMACEUTICALS INC | 1.4M | $41.2M | 1.8% | — | — | 2 qtrssince 2018-Q4 | Unchanged 0 |
KALA PHARMACEUTICALS INC | 4.5M | $37.5M | 1.6% | $12,225.00 | +69.12% | 2 qtrssince 2018-Q4 | Unchanged 0 |
MOMENTA PHARMACEUTICALS INC | 2.6M | $37.3M | 1.6% | — | — | 2 qtrssince 2018-Q4 | Increased 47 |
DICERNA PHARMACEUTICALS INC | 2.5M | $36M | 1.6% | — | — | 2 qtrssince 2018-Q4 | Unchanged 0 |
EIGER BIOPHARMACEUTICALS INC | 2.4M | $33.8M | 1.5% | — | — | 2 qtrssince 2018-Q4 | Unchanged 0 |
RA CAPITAL MANAGEMENT, L.P. manages $2.3B across 29 positions as of Q1 2019. Top holdings: ASND (21.0%), WVE (13.0%), THOR (8.5%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 2/5.0.
Active quarter - 6 new positions, 2 exits, 4 increased. Top move: SAGE (NEW, conviction 77). Portfolio: $2.3B across 29 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR